Yisheng Lai

6PUBLICATIONS
7CO-AUTHORS
Biologically active moleculesCheminformatics and quantitative structure-activity relationshipsBiomolecular modelling and designApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 26, 2026
Discovery of Pyrrolo[1',2':1,6]pyrimido[5,4-c]pyridazin-6(5H)-one Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Inhibitors.

|Oct 10, 2024
Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase.

Yu Xu, Dan Liu, Wenzhuang Zhang

|Sep 14, 2023
Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced hERG Inhibitory Activity for the Treatment of Acute Myeloid Leukemia.

Qingyun Wei, Kun Yao, Jie Yang

|Jun 20, 2022
Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy.

Wen Liu, Yi Zou, Kaiming Li

|May 26, 2021
Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.

Yiqiang OuYang, Jian Gao, Lei Zhao

|May 30, 2020
Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo.

Shushan Ge, Haiqing Zhong, Xuewei Ma

Pageof 1

Frequent Collaborators

2 joint publications

Wenjie Guo

2 joint publications

Yu Xu

1 joint publications

Shushan Ge

1 joint publications

Yi Zou